Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Vertex Pays Alios $60M Up Front for Worldwide Rights to Two Phase I-Ready HCV Therapeutics

Aim is to combine ALS-2200 and ALS-2158 with approved Incivek and investigational candidate VX-222.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll